THIS WEBSITE IS FOR
HEALTHCARE PROFESSIONALS

 

This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) who are interested in information on ROZLYTREK®. If you are a US healthcare professional click here. The product has received EMA approval. The registration status and approved product labels of ROZLYTREK® may not be the same in the different countries. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details. 

Request medical information

Prescribing information

Contact us

Rozlytrek logo, home page

  • What is ROZLYTREK?
     
  • Introduction to ROZLYTREK
  • MoA and CNS activity
  • ROS1+ NSCLC
     
  • Study design
  • Patient characteristics
  • Efficacy
  • CNS efficacy
  • NTRK fusion+ solid tumours
     
  • Study design
  • Patient characteristics
  • Efficacy
  • CNS efficacy
  • ROZLYTREK safety overview
     
  • ROZLYTREK safety summary
  • ROZLYTREK adverse reactions
  • Monitoring
  • Prescribing ROZLYTREK
     
  • ROZLYTREK dosing
  • Download the ROZLYTREK SmPC
  • Patient benefits
     
  • Lung cancer patient
  • Breast cancer patient
  • Sarcoma patient
  • Gene fusion detection
     
  • Introduction to clinically actionable fusions
  • NTRK
  • ROS1
  • Testing guidelines
  • Disease support
     
  • Coming soon
Request medical information

Prescribing information

Contact us

Bring the potential of ROZLYTREK® to life

Disease support

Disease support

Coming soon

© 2021. RF. Hoffmann-La Roche Ltd.

About Roche

Contact Us
Legal statement
Privacy

Cookie Preferences

Your local partner

M-XX-00003955 Date of preparation: July 2021

This site is intended for those outside the United States.